(Q51062345)

28 March 2018

title

Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. (English)

1 reference

28 March 2018

0 references

0 references

5

1 reference

28 March 2018

Michael Maes

6

1 reference

28 March 2018

author name string

Capuron L

1

1 reference

28 March 2018

Ravaud A

2

1 reference

28 March 2018

Gualde N

3

1 reference

28 March 2018

Bosmans E

4

1 reference

28 March 2018

Neveu PJ

7

1 reference

28 March 2018

publication date

1 November 2001

1 reference

28 March 2018

published in

Psychoneuroendocrinology

1 reference

28 March 2018

volume

26

1 reference

28 March 2018

page(s)

797-808

1 reference

28 March 2018

issue

8

1 reference

28 March 2018

Saturable transport of peptides across the blood-brain barrier

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900030-0

7 January 2021

Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900030-0

7 January 2021

Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900030-0

7 January 2021

The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900030-0

7 January 2021

The immunobiological effects of interleukin-2 in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900030-0

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900030-0

7 January 2021

Fever: role of pyrogens and cryogens

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900030-0

7 January 2021

A major binding protein for leukemia inhibitory factor in normal mouse serum: identification as a soluble form of the cellular receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900030-0

7 January 2021

Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900030-0

7 January 2021

Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900030-0

7 January 2021

In vivo time and dose dependency of interleukin-6 secretion in response to low-dose subcutaneous recombinant interleukin-2

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900030-0

7 January 2021

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900030-0

7 January 2021

Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900030-0

7 January 2021

Cytokine production and serum proteins in depression

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900030-0

7 January 2021

Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900030-0

7 January 2021

Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900030-0

7 January 2021

Indicators of immune activation in major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900030-0

7 January 2021

Leukemia inhibitory factor: part of a large ingathering family

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900030-0

7 January 2021

Induction of circulating interleukin 10 by interleukin 1 and interleukin 2, but not interleukin 6 immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900030-0

7 January 2021

Interleukin-2 does not cross the blood-brain barrier by a saturable transport system.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900030-0

7 January 2021

Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900030-0

7 January 2021

Endotoxin produces a depressive-like episode in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900030-0

7 January 2021

10.1016/S0306-4530(01)00030-0

Identifiers

DOI

1 reference

28 March 2018

PubMed ID

11585680

1 reference

28 March 2018